Adlai Nortye Group (ANL) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Savara (SVRA) over the past year, gaining 796.5% versus a gain of 39.2%. Savara is the larger company by market cap ($1.01 billion vs $1.01 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | SVRA |
|---|---|---|
| Share price | $15.62 | $4.92 |
| Market cap | $1.01B | $1.01B |
| 1-day change | +0.71% | +1.86% |
| YTD return | +992.25% | -19.90% |
| 1-year return | +796.53% | +39.19% |
| 5-year return | — | +274.42% |
| EPS (TTM) | $-0.66 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $7.01 |
| 52-week low | $0.879 | $3.35 |
| Distance from 52-week high | -9.45% | -29.76% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +88.86% | +124.80% |
| Average volume | 187.30K | 1.83M |
| Shares outstanding | 58.73M | 205.46M |
| Employees | 109 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed SVRA by 757.3 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
ANL vs SVRA FAQ
Which is bigger, Adlai Nortye Group or Savara?
Savara (SVRA) is larger, with a market capitalization of $1.01B compared with $1.01B for Adlai Nortye Group (ANL).
Which stock has performed better over the past year, ANL or SVRA?
ANL returned +796.53% over the past 12 months, compared with +39.19% for SVRA (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.